Read more on the ACHIEVE-3 results here: To view or add a comment, sign in Novo Nordisks next-generation obesity drug CagriSema failed to outperform Eli Lillys Zepbound in a recent head-to-head Phase 3 trial, missing its primary goal and underscoring the intense competition and high stakes in the obesity drug market
Blend well to ensure even application
IV/IM Dosage: 2-3 vials every 3 days Method : 1 vial, two times weekly by sub-lingual administration, or as advised by your physician
it offers numerous health benefits
Of these, severe AEs were reported by 16 participants treated with survodutide (5.3%), four receiving placebo (6.8%) and none receiving semaglutide
After publication of our Green Tea Review last month, a CL member emailed us about the potential danger of getting too much fluoride from tea